Spyre Therapeutics Inc (SYRE) 뉴스

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Feb. 7, 2025 WALTHAM...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts PR...

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM...

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire WALTHAM, Mass., Dec. 18, 2024 WALTHAM...

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Dec. 2, 2024 WALTHAM...

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A...

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire WALTHAM...